Drug Discovery Today

Article	Citations
Contents page 2	223
Contents page	208
Adjunctive therapy for multidrug-resistant bacterial infections: Type III secretion system and efflux inhibitors	190
Mitochondrial dysfunction: A potential target for Alzheimer’s disease intervention and treatment	185
Multiple strategies for the treatment of invasive breast carcinoma: A comprehensive prospective	156
Specificity of pharmacokinetic modeling of nanomedicines	138
Demystifying the potential of inhibitors targeting DNA topoisomerases in unicellular protozoan parasites	133
A global bibliometric and visualized analysis of bacteria-mediated cancer therapy	120
Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity	117
Trends in oral small-molecule drug discovery and product development based on product launches before and after the Rule of Five	114
Opportunities and challenges in drug discovery targeting the orphan receptor GPR12	111
Double-edged sword: Therapeutic efficacy versus toxicity evaluations of doped titanium implants	106
Models and approaches to comprehend and address glial inflammation following spinal cord injury	104
Repurposing of parenterally administered active substances used to treat pain both systemically and locally	104
The recent progress of deep-learning-based in silico prediction of drug combination	104
Small-molecule modulators of the circadian clock: Pharmacological potentials in circadian-related diseases	97
Dysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies	95
CIPDB: A biological structure databank for studying cation and π interactions	91
Recent development in the design of small ‘drug-like’ and nanoscale glycomimetics against Escherichia coli infections	86
Tubulin targeting agents and their implications in non-cancer disease management	85
Gastroretentive drug delivery systems: A holy grail in oral delivery	85
General aspects of powder rheology applied to pharmaceutical formulations	81
The potential value of 5-androstenediol in countering acute radiation syndrome	78
Development of JmjC-domain-containing histone demethylase (KDM2-7) inhibitors for cancer therapy	77
Computational modeling approaches and regulatory pathways for drug combinations	76

The global status of bioequivalence trials: a comprehensive clinical trial landscape analysis based on the Trialtrove database	76
Generative AI: driving productivity and scientific breakthroughs in pharmaceutical R&D	73
Advancing drug repurposing research: Trends, collaborative networks, innovation and knowledge leaders	73
Targeted drug delivery to the retinal pigment epithelium: Untapped therapeutic potential for retinal diseases	73
Antibody–drug conjugates: What drives their progress?	72
Redox active or thiol reactive? Optimization of rapid screens to identify less evident nuisance compounds	72
From promise to progress: the dynamic landscape of glioblastoma immunotherapy	72
Contents page 2	71
Exploration of small-molecule inhibitors targeting Hsp110 as novel therapeutics	71
Advancing pharmacogenetics research in Africa: the “Project Africa GRADIENT” initiative	70
Randomized controlled trials do not always fit the purpose: A science-based response to Venetis and Mol’s editorial on biosimilars of follitropin alfa	68
Recent advancements in mass spectrometry for higher order structure characterization of protein therapeutics	67
Overcoming the protein corona in chitosan-based nanoparticles	67
Organoids in modelling infectious diseases	66
Medicinal chemistry aspects of uracil containing dUTPase inhibitors targeting colorectal cancer	66
Pathogenic TDP-43 in amyotrophic lateral sclerosis	64
Steps toward nebulization in-use studies to understand the stability of new biological entities	63
Systematic review and QSPR analysis of chemical penetration through the nail to inform onychomycosis candidate selection	63
Investigating miRNA subfamilies: Can they assist in the early diagnosis of acute myocardial infarction?	60
The emerging role of fatty acid binding protein 7 (FABP7) in cancers	59
MTHFD2: A significant mitochondrial metabolic enzyme and a novel target for anticancer therapy	58
The main aspects of non-clinical studies required for obtaining marketing authorisation for small molecules and biologics/biopharmaceuticals in the European Union and the United States	58
MRI assessment of cerebral perfusion in clinical trials	58
Unlocking therapeutic frontiers: harnessing artificial intelligence in drug discovery for neurodegenerative diseases	57
Master protocols and other innovative trial designs in inflammation and immunology to expedite clinical drug development	56
Lactose in tablets: Functionality, critical material attributes, applications, modifications and co-processed excipients	55
Bridging informatics and medicinal inorganic chemistry: Toward a database of metallodrugs and metallodrug candidates	54
Caught between a ROCK and a hard place: current challenges in structure-based drug design	54
ImmunoPET imaging of hematological malignancies: From preclinical promise to clinical reality	54
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options	53
A review on the recent advances of interaction studies of anticancer metal-based drugs with therapeutic targets, DNA and RNAs	53
Embryonic and larval zebrafish models for the discovery of new bioactive compounds against tuberculosis	51
Translational PK/PD: a retrospective analysis of performance and impact from a drug portfolio	50
Targeting mutant EGFR in non-small cell lung cancer in the context of cell adaptation and resistance	50
Lipid- and polymer-based formulations containing TNF-α inhibitors for the treatment of inflammatory bowel diseases	49
Role of siRNA-based nanocarriers for the treatment of neurodegenerative diseases	49
Recent advances in Clp protease modulation to address virulence, resistance and persistence of MRSA infection	49
Mutation informatics: SARS-CoV-2 receptor-binding domain of the spike protein	48
Molecular approaches for the treatment and prevention of Friedreich's ataxia	48
PD-L1 small-molecule modulators: A new hope in epigenetic-based multidrug cancer therapy?	48
Targeted protein degradation: current molecular targets, localization, and strategies	48
Recent advances towards overcoming the blood–brain barrier	47
Oral delivery of nucleic acid therapeutics: Challenges, strategies, and opportunities	47
Towards Pharma 4.0 in clinical trials: A future-orientated perspective	47
Metabolic reprogramming: Unveiling the therapeutic potential of targeted therapies against kidney disease	47
50 shades of AI in regulatory science	46
IRE1α-mediated UPR activation in gastrointestinal cancers: Adaptive mechanisms and therapeutic potential	46
Global or local: The future of biotech	46
Overview of new indications for novel drugs approved in China between 2018 and 2024	46
Opioid epidemic and the urge to discover new treatment options	46

Contents page 2	46
Genetic–epigenetic targets for PCOS-associated diabesity	45
Sustainability by design for recombinant protein therapeutics	45
Contents page	45
Illuminating function of the understudied druggable kinome	45
Potential nanocarrier-mediated miRNA-based therapy approaches for multiple sclerosis	44
Regulatory readiness to facilitate the appropriate use of innovation in clinical trials: The case of decentralized clinical trial approaches	44
Back on the scene: Advances and challenges in CD3-related drugs in tumor therapy	44
Review of the impact of the FDA’s Fast Track Designation on biotechnology companies’ share prices	43
Recent insights into viral infections as a trigger and accelerator in alzheimer's disease	43
UCP1 activation: Hottest target in the thermogenesis pathway to treat obesity using molecules of synthetic and natural origin	42
An overview of progress in human metapneumovirus (hMPV) research: Structure, function, and therapeutic opportunities	42
Elevating life science R&D success with AI: a framework	42
Cubosome-based cosmeceuticals: A breakthrough in skincare	41
Self-amplifying mRNA vaccines: Mode of action, design, development and optimization	41
Hippo signaling in acute kidney injury to chronic kidney disease transition: Current understandings and future targets	41
Recent advances in multitarget-directed ligands via in silico drug discovery	40
Drugs from drugs: New chemical insights into a mature concept	40
Advancements and challenges in using AI for biomarker detection in early Alzheimer’s disease	40
The role of gut microbial β-glucuronidase in drug disposition and development	40
Quantum computing's potential for drug discovery: Early stage industry dynamics	40
CPPsite3: An updated large repository of experimentally validated cell-penetrating peptides	39
In silico resources help combat cancer drug resistance mediated by target mutations	39
Recent advances in dual-drug co-amorphous systems	39
Renal cell carcinoma therapy: Current and new drug candidates	39
Impact of HDAC inhibitors on macrophage polarization to enhance innate immunity against infections	38
Decentralised, patient-centric, site-less, virtual, and digital clinical trials? From confusion to consensus	38
Vaginal drug delivery system: A promising route of drug administration for local and systemic diseases	38
Open innovation: A paradigm shift in pharma R&D?	38
Pharmaceutical strategies for the treatment of bacterial biofilms in chronic wounds	38
Strategizing the human microbiome for small molecules: Approaches and perspectives	37
Transforming patient engagement in clinical trials: Moving from a transactional relationship to human-centered care	37
The Unitary Patent and UPC – Implications for the pharmaceutical sector	37
Nanoformulations of chemotherapeutic activators of the cGAS–STING pathway in tumor chemoimmunotherapy	37
Real-world data in drug development strategies for orphan drugs: Tafasitamab in B-cell lymphoma, a case study for an approval based on a single-arm combination trial	37
Artificial intelligence methods in kinase target profiling: Advances and challenges	36
Corrigendum to “Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors” [Drug Discov. Today 28(1) (2023) 103394]	36
Advances in lipid-based nanoformulations for inhaled antibiotic therapy in respiratory infections	36
dbDNA™: An advanced platform for genetic medicines	36
Neurotrophin peptidomimetics for the treatment of neurodegenerative diseases	36
Artificially engineered bacteria to treat gastrointestinal disease and cancer	36
Small molecules targeting canonical transient receptor potential channels: an update	36
A new era for schizophrenia drug development – Lessons for the future	35
Approaches to advance drug discovery for neglected tropical diseases	35
Therapeutic targeting of the complement system in ocular disease	35
Oncological drug discovery: AI meets structure-based computational research	35
Compound–protein interaction prediction by deep learning: Databases, descriptors and models	34
Breakthrough in RAS targeting with pan-RAS(ON) inhibitors RMC-7977 and RMC-6236	34
Metabophore-mediated retro-metabolic (‘MeMeReMe’) approach in drug design	34
Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches	34
Targeting hepatitis B virus cccDNA levels: Recent progress in seeking small molecule drug candidates	34
Science of, and insights into, thermodynamic principles for dermal formulations	34
Computational resources in the management of antibiotic resistance: Speeding up drug discovery	34
Corrigendum to “Role of transient receptor potential channels in the regulation of vascular tone” [Drug Discov. Today 29(7) (2024) 104051]	34
Recent advances in flavonoid-based nanocarriers as an emerging drug delivery approach for cancer chemotherapy	33
PROTAC technology: A new drug design for chemical biology with many challenges in drug discovery	33
2023 in review: FDA approvals of new medicines	33
Geometric deep learning methods and applications in 3D structure-based drug design	33
Therapeutic potential of targeting IL-17 and its receptor signaling in neuroinflammation	33
The expanding repertoire of covalent warheads for drug discovery	33
Druggable genome special issue: An introduction	33
Molecular medicinal insights into scaffold hopping-based drug discovery success	33
Contents page	32
The importance of a go-to-market strategy in the commercialisation of cellular immunotherapies	32
Expanding therapeutic potential of Bdellovibrio bacteriovorus against multidrug-resistant pathogens	32
Regulatory oversight on the use of experimental therapies during a pandemic: The case of early access to convalescent plasma therapy in three LMICs	32
How health technology assessment can help to address challenges in drug repurposing: a conceptual framework	32
A retrospective regulatory analysis of FDA recalls carried out by pharmaceutical companies from 2012 to 2023	32
Corrigendum to “Pharmacological modulation of autophagy for epilepsy therapy: Opportunities and obstacles” [Drug Discov. Today 28(6) (2023) 103600]	32
Death ligand receptor (DLR) signaling: Its non-apoptotic functions in cancer and the consequences of DLR-directed therapies	31
Harnessing personalized tailored medicines to digital-based data-enriched edible pharmaceuticals	31
‘Home inspections’ for life sciences companies going public before clinical proof-of-concept	31
The era of gene therapy: From preclinical development to clinical application	31
Corrigendum to “Critical path activities in clinical trial setup & conduct – How to avoid bottlenecks and accelerate clinical trials” [Drug Discov. Today 28(10) (2023) 103733]	31
Peptide-derived ligands for the discovery of safer opioid analgesics	31
Harnessing G-quadruplex ligands for lung cancer treatment: A comprehensive overview	31
Publisher’s Note	31
Targeting autophagy in colorectal cancer: An update on pharmacological small-molecule compounds	31
Challenges and opportunities in the discovery, development, and commercialization of pathogen-targeted antibiotics	31
A pipeline analysis of advanced therapy medicinal products	31

Advancing ocular gene therapy: a machine learning approach to enhance delivery, uptake and gene expression	31
RhoA activation-mediated vascular permeability in capillary malformation-arteriovenous malformation syndrome: a hypothesis	30
Nanomedicine approaches to reduce cytokine storms in severe infections	30
Effectiveness of histamine receptor antagonists in the treatment of histamine-driven clinical symptoms: do we have a histamine or, better, an anti-histamine problem?	30
Regulating NETosis: An emerging facet of statin pleiotropy	30
Drugging the entire human proteome: Are we there yet?	30
Exosome-mediated PROTAC delivery for treatment of RNA viral infections and zoonosis	30
IdopNetwork as a genomic predictor of drug response	30
Early career researchers’ experiences in drug discovery in Africa	30
Orphan GPR52 as an emerging neurotherapeutic target	30
Competition of regulatory ecosystems in approving medicines: policy implications in the case of Europe	29
Recent discoveries of the role of histone modifications and related inhibitors in pathological cardiac hypertrophy	29
Machine learning and natural language processing in clinical trial eligibility criteria parsing: a scoping review	29
Opportunities and challenges of physiologically based pharmacokinetic modeling in drug delivery	29
Nanophotonic waveguide-based sensing of circulating cell-free mitochondrial DNA: implications for personalized medicine	29
Chiral-engineered supraparticles: Emerging tools for drug delivery	29
Using computers to ESKAPE the antibiotic resistance crisis	29
COVID-19 therapeutics: Small-molecule drug development targeting SARS-CoV-2 main protease	29
Evaluating the performance of drug-repurposing technologies	29
ADAM10: Function insights, disease implications, and promise of therapeutic targeting	29
Deadly interactions: Synergistic manipulations of concurrent pathogen infections potentially enabling future pandemics	29
TDP-43 protein interactome informs about perturbed canonical pathways and may help develop personalized medicine approaches for patients with TDP-43 pathology	29
Antimicrobial and anti-biofilm activities of bio-inspired nanomaterials for wound healing applications	29
Social media mining in drug development—Fundamentals and use cases	28
Targeting SIRT1-regulated autophagic cell death as a novel therapeutic avenue for cancer prevention	28
Surface-enhanced Raman scattering biosensors for detection of oncomiRs in breast cancer	28
Spare and repair the gut microbiota from antibiotic-induced dysbiosis: state-of-the-art	28
Recent progress in covalent organic frameworks for cancer therapy	28
Translating precision medicine for autism spectrum disorder: A pressing need	28
A personalized pharmaco-epistatic network model of precision medicine	27
Identification of biological targets through the correlation between cell line chemosensitivity and protein expression pattern	27
Integrating heterogeneous data to facilitate COVID-19 drug repurposing	27
Generic dry powder inhalers bioequivalence: Batch–to-batch variability insights	27
Innovation in breakthrough drugs and vaccines: Development risk, patient impact, and value	27
A review of the efficacy of prostate cancer therapies against castration-resistant prostate cancer	27
Peptide modulators of cell migration: Overview, applications and future development	27
Therapies for Inherited Retinal Dystrophies: What is Enough?	27
Biopharmaceutical R&D outsourcing: Short-term gain for long-term pain?	27
Patents, trade secrets and pricing	27
Sustaining pharmaceutical innovation after the Inflation Reduction Act: trends in R&D spending, equity investment, and business development	26
Recent advances in the molecular design and applications of viral RNA-targeting antiviral modalities	26
Therapeutic potential of fucosyltransferases in cancer and recent development of targeted inhibitors	26
Novel and investigational therapies for wet and dry age-related macular degeneration	26
Beyond CL and VSS: A comprehensive approach to human pharmacokinetic predictions	26
Which cryptic sites are feasible drug targets?	26
Web resources facilitate drug discovery in treatment of COVID-19	26
Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review	26
Electron diffraction: Accelerating drug development	25
Nanofibers as drug-delivery systems for antimicrobial peptides	25
Can preclinical drug development help to predict adverse events in clinical trials?	25
Optical tweezers for drug discovery	25
Clinical significance and potential role of trimethylamine N-oxide in neurological and neuropsychiatric disorders	25
Contents page	25
Recent trends in targeted delivery of smart nanocarrier-based microbial enzymes for therapeutic applications	25
Applications of density functional theory in COVID-19 drug modeling	25
Comparative analysis of FDA approvals by top 20 pharma companies (2014–2023)	25
ATP-binding cassette efflux transporters and MDR in cancer	25
Active pharmaceutical ingredients (APIs) in ionic liquids: An effective approach for API physiochemical parameter optimization	25
New approaches for challenging therapeutic targets	25
Trends, challenges, and success factors in pharmaceutical portfolio management: Cognitive biases in decision-making and their mitigating measures	25
Benefits of hybrid QM/MM over traditional classical mechanics in pharmaceutical systems	25
Concepts and applications of chemical fingerprint for hit and lead screening	25
Prospects of halofuginone as an antiprotozoal drug scaffold	25
Contents page	24
How can MSI enhance our understanding of ASO distribution?	24
Statins and angiogenesis in non-cardiovascular diseases	24
Metallocompounds as anticancer agents against osteosarcoma	24
Contents page	24
Corrigendum to ‘Synthetic lethality: a step forward for personalized medicine in cancer’ [Drug Discov. Today 25 (2020) 305–320]	24
Grasping cryptic binding sites to neutralize drug resistance in the field of anticancer	24
Extrapolation: Experience gained from original biologics	24
Informatic challenges and advances in illuminating the druggable proteome	24
Rapid progress in neuroimaging technologies fuels central nervous system translational medicine	24
Aceclofenac and methotrexate combination therapy could influence Th1/Th17 axis to modulate rheumatoid-arthritis-induced inflammation	23
How missing value imputation is confounded with batch effects and what you can do about it	23
The forced swim test has poor accuracy for identifying novel antidepressants	23
Illuminating the druggable genome: Pathways to progress	23
Epigenetic roles of lysine-specific demethylase 1 (LSD1) in cancer metabolism	23
On the pivotal role of drug discovery in sustainable EU pharma reform	23
Brain-derived neurotrophic factor (BDNF) in perinatal depression: Side show or pivotal factor?	23
SET7, a lysine-specific methyl transferase: An intriguing epigenetic target to combat diabetic nephropathy	23
Integrated nanomaterials for non-invasive photothermal therapy of rheumatoid arthritis	23
An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020	23
DDR1-targeted therapies: current limitations and future potential	23
Pharmaceutical nanocrystals: A promising approach for improved topical drug delivery	23
Nanosponges: An overlooked promising strategy to combat SARS-CoV-2	23
Dual-action potential of cationic cryptides against infections and cancers	23
Development and therapeutic implications of small molecular inhibitors that target calcium-related channels in tumor treatment	22
Therapeutic potential of acetyl-DL-leucine and its L-enantiomer in posterior fossa syndrome: Mechanistic insights	22
Impact of the diseased lung microenvironment on the in vivo fate of inhaled particles	22
Novel therapeutic targets for cardiorenal syndrome	22
Chemical space visual navigation in the era of deep learning and Big Data	22
Anti-amyloid potential of some phytochemicals against Aβ-peptide and α-synuclein, tau, prion, and Huntingtin protein	22
Advances in antibody phage display technology	22
Stimulating development of innovative medicines in the European Union: does a new definition for unmet medical need add value?	22